Skip to main content
. 2020 Apr 3;3:163. doi: 10.1038/s42003-020-0882-8

Fig. 7. HOIPIN-1 shows therapeutic effects on psoriasis.

Fig. 7

a Phenotypical presentation of mouse back skin after 5 days of treatment. BALB/c mice (8-week-old female) were treated daily with control vaseline or imiquimod cream, in the presence of clobetasol or 0.1% HOIPIN-1 in DMSO. b HOIPIN-1 alleviates imiquimod-induced psoriasis. Erythema, scaling, and thickness of the back skin were scored daily on a scale from 0 to 4, and the cumulative scores (means, n = 3) are shown. c HOIPIN-1 reduces the thickened epidermis induced by the imiquimod treatment. Mice were treated for 7 days with imiquimod, clobetasol, and/or HOIPIN-1, as indicated. H&E staining of the back skin was performed. Bars, 50 μm. d The thickness of the epidermis, at 90–132 sites from three to four mice treated as indicated, was measured using the ImageJ software (National Institutes of Health, Bethesda, MD) and statistically analyzed. e HOIPIN-1 suppresses cytokine expression in the back skin of imiquimod-treated mice. The mRNA levels of Il17a, Il17f, Il22, and Il23a in the back skin of the mice were examined by TaqMan PCR. Data are shown as means ± SEM. In d, e, NS not significant, *P < 0.05, **P < 0.01, ****P < 0.0001, by one-way ANOVA with Tukey’s post hoc test.